Pain Medicine Physician, Millennium Pain Center, Bloomington, Illinois 61701, USA.
Pain Pract. 2012 Mar;12(3):194-201. doi: 10.1111/j.1533-2500.2011.00489.x. Epub 2011 Jul 29.
In a prospective observational study conducted in an urban pain management center, we evaluated whether spinal cord stimulation (SCS) is effective in relieving discogenic pain of IDD origin.
Thirteen patients with intractable discogenic low back pain were enrolled. Four patients never underwent permanent implantation due to insurance denial, medical reasons or failed trial and served as a control group. Nine patients underwent SCS implantation (treatment group). All patients were followed for 12 months and assessed at each interval for pain (NRS), disability (ODI), and opioid use.
Nine patients completed the SCS trial with > 50% pain relief. The pretrial NRS score was 7.8 ± 0.5 mm in treated patients vs. 6.5 ± 1.7 mm in control patients. At 3, 6 and 12 months, the NRS was reduced to 2.9 ± 0.7 mm, 1.7 ± 0.5 mm, and 2.9 ± 0.5 mm, respectively in treated patients. NRS was unchanged in the control patients (6.5 ± 1.9 mm). The ODI score prior to the SCS trial in treated patients was 53.1 ± 3.4% vs. 54.0 ± 20.5 in control patients. At 3, 6 and 12 months the ODI scores were 39.0 ± 8.0%, 38.7 ± 4.6%, and 41.1 ± 3.9%, respectively in the treated patients, and 48.5 ± 29.5 at 12 months in control patients. In 6 patients receiving opioids prior to the SCS trial, average consumption was reduced by 69% (P = 0.036) over 12 months of therapy as compared with a 54% increase in the control patients. SCS usage was stable over the 12-month study.
The current study indicates that SCS may provide effective pain relief, improve disability, and reduce opioid usage in patients with discogenic pain.
在一项前瞻性观察性研究中,我们在一家城市疼痛管理中心评估脊髓刺激(SCS)是否能有效缓解椎间盘源性疼痛(IDD)。
共纳入 13 例难治性椎间盘源性腰痛患者。4 例患者因保险拒绝、医疗原因或试验失败而从未进行永久性植入,作为对照组。9 例患者行 SCS 植入(治疗组)。所有患者均随访 12 个月,并在每个随访间隔评估疼痛(NRS)、残疾(ODI)和阿片类药物使用情况。
9 例患者完成 SCS 试验,疼痛缓解率>50%。治疗前 NRS 评分在治疗组为 7.8 ± 0.5mm,在对照组为 6.5 ± 1.7mm。治疗后 3、6 和 12 个月,NRS 分别降至 2.9 ± 0.7mm、1.7 ± 0.5mm 和 2.9 ± 0.5mm。对照组 NRS 无变化(6.5 ± 1.9mm)。治疗前 SCS 试验时,治疗组 ODI 评分为 53.1 ± 3.4%,对照组为 54.0 ± 20.5%。治疗后 3、6 和 12 个月,治疗组 ODI 评分分别为 39.0 ± 8.0%、38.7 ± 4.6%和 41.1 ± 3.9%,对照组为 48.5 ± 29.5%。在 6 例 SCS 试验前接受阿片类药物治疗的患者中,与对照组相比,治疗 12 个月后平均阿片类药物消耗量减少 69%(P = 0.036)。SCS 使用在 12 个月的研究中保持稳定。
本研究表明,SCS 可能为椎间盘源性疼痛患者提供有效止痛、改善残疾和减少阿片类药物使用。